{"doc_id": "33158717", "type of study": "Therapy", "title": "", "abstract": "Shufeng Jiedu, a promising herbal therapy for moderate COVID-19:Antiviral and anti-inflammatory properties, pathways of bioactive compounds, and a clinical real-world pragmatic study.\nShufeng Jiedu capsules (SFJDC), a patented herbal drug composed of eight medicinal plants, is used for the treatment of different viral respiratory tract infectious diseases.\nBased on its antiviral, anti-inflammatory and immunoregulatory activity in acute lung injury, SFJDC might be a promising candidate for the treatment of COVID-19.\nTo evaluate the antiviral and anti-inflammatory properties and to discover the mechanism of action of SFJDC as a potential drug for the treatment of COVID-19.\nFurthermore, the study should determine the clinical effectiveness of SFJDC for the treatment of COVID-19.\nWe analyzed the antiviral and anti-inflammatory effects of SFJDC in a HCoV-229E mouse model on lung index, virus load in the lung, the release of cytokines, and on T- and B-lymphocytes.\nThe mechanism of action was further investigated by network analysis.\nAdditionally, we investigated data from a clinical pragmatic real-world study for patients with confirmed COVID-19, to evaluate the clinical effect of SFJDC and to determine the best time to start the treatment.\nSFJDC significantly reduced the virus load in the lung of HCoV-229E mice (from 1109.29 \u00b1 696.75 to 0 \u00b1 0 copies/ml), decreased inflammatory factors IL-6, IL-10, TNF-\u03b1, and IFN-\u03b3 in the lung, and increased the amount of CD4+ and CD8+ cells in the blood compared to the model group.\nNetwork analysis revealed that SFJDC reduces the activity of NF\u03baB via several signaling pathways.\nQuercetin, wogonin, and polydatin bind directly to the main protease (Mpro) of SARS-CoV-2.\nClinical data showed that SFJDC, added to standard antiviral therapy (AVD), significantly reduced the clinical recovery time of COVID-19 and fatigue (from 3.55 \u00b1 4.09 to 1.19 \u00b1 2.28 days) as well as cough (from 5.67 \u00b1 5.64 to 3.47 \u00b1 3.75) days compared to AVD alone.\nSFJDC therapy was significantly more effective when used within the first 8 days after the onset of symptoms.\nSFJDC might be a promising drug for the treatment of COVID-19, but large-scale randomized, double-blinded, placebo-controlled clinical trials are needed to complement the real-world evidence.\nIt might be beneficial to start SFJDC treatment as early as possible in suspected cases of COVID-19.\nCopyright \u00a9 2020 The Author(s).\nPublished by Elsevier GmbH.. All rights reserved.\n", "Evidence Map": {"Enrollment": [{"term": "moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 47, "end": 64}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 149, "end": 157}, {"term": "confirmed COVID-19", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 115}, {"term": "HCoV-229E", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 67}, {"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 132, "end": 140}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Shufeng Jiedu , a promising herbal therapy for moderate COVID-19 : Antiviral and anti-inflammatory properties , pathways of bioactive compounds , and a clinical real-world pragmatic study .", "Evidence Elements": {"Participant": [{"term": "moderate COVID-19", "negation": "affirmed", "UMLS": {}, "start": 47, "end": 64}], "Intervention": [{"term": "Shufeng Jiedu", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 13, "has_chemical": [{"text": "shufeng jiedu", "maps_to": "C4309970:shufeng jiedu", "start": 0, "end": 13}], "has_relation": "N/A"}], "Outcome": [{"term": "Antiviral and anti-inflammatory properties", "negation": "affirmed", "UMLS": {}, "start": 67, "end": 109}, {"term": "pathways of bioactive compounds", "negation": "affirmed", "UMLS": {}, "start": 112, "end": 143}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Shufeng Jiedu capsules ( SFJDC ) , a patented herbal drug composed of eight medicinal plants , is used for the treatment of different viral respiratory tract infectious diseases .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "BACKGROUND", "Text": "Based on its antiviral , anti-inflammatory and immunoregulatory activity in acute lung injury , SFJDC might be a promising candidate for the treatment of COVID-19 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PURPOSE", "Text": "To evaluate the antiviral and anti-inflammatory properties and to discover the mechanism of action of SFJDC as a potential drug for the treatment of COVID-19 .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 149, "end": 157}], "Intervention": [{"term": "SFJDC", "negation": "affirmed", "UMLS": {}, "start": 102, "end": 107, "has_chemical": [{"text": "shufeng jiedu capsules", "maps_to": "C0006935:capsules", "start": 0, "end": 22, "has_form": ["capsules"]}], "has_relation": "N/A"}], "Outcome": [{"term": "antiviral and anti-inflammatory properties", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 58}, {"term": "mechanism of action", "negation": "affirmed", "UMLS": {}, "start": 79, "end": 98}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PURPOSE", "Text": "Furthermore , the study should determine the clinical effectiveness of SFJDC for the treatment of COVID-19 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "DESIGN", "Text": "We analyzed the antiviral and anti-inflammatory effects of SFJDC in a HCoV-229E mouse model on lung index , virus load in the lung , the release of cytokines , and on T- and B-lymphocytes .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "SFJDC", "negation": "affirmed", "UMLS": {}, "start": 59, "end": 64, "has_chemical": [{"text": "shufeng jiedu capsules", "maps_to": "C0006935:capsules", "start": 0, "end": 22, "has_form": ["capsules"]}], "has_relation": "N/A"}], "Outcome": [{"term": "antiviral and anti-inflammatory effects", "negation": "affirmed", "UMLS": {}, "start": 16, "end": 55}, {"term": "lung index", "negation": "affirmed", "UMLS": {}, "start": 95, "end": 105}, {"term": "virus load in the lung", "negation": "affirmed", "UMLS": {}, "start": 108, "end": 130}, {"term": "release of cytokines", "negation": "affirmed", "UMLS": {}, "start": 137, "end": 157}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "DESIGN", "Text": "The mechanism of action was further investigated by network analysis .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "mechanism of action", "negation": "affirmed", "UMLS": {}, "start": 4, "end": 23}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "DESIGN", "Text": "Additionally , we investigated data from a clinical pragmatic real-world study for patients with confirmed COVID-19 , to evaluate the clinical effect of SFJDC and to determine the best time to start the treatment .", "Evidence Elements": {"Participant": [{"term": "confirmed COVID-19", "negation": "affirmed", "UMLS": {}, "start": 97, "end": 115}], "Intervention": [{"term": "SFJDC", "negation": "affirmed", "UMLS": {}, "start": 153, "end": 158, "has_chemical": [{"text": "shufeng jiedu capsules", "maps_to": "C0006935:capsules", "start": 0, "end": 22, "has_form": ["capsules"]}], "has_relation": "N/A"}], "Outcome": [{"term": "clinical effect", "negation": "affirmed", "UMLS": {}, "start": 134, "end": 149}, {"term": "best", "negation": "affirmed", "UMLS": {}, "start": 180, "end": 184}, {"term": "to start", "negation": "affirmed", "UMLS": {}, "start": 190, "end": 198}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "SFJDC significantly reduced the virus load in the lung of HCoV-229E mice ( from 1109.29 \u00b1 696.75 to 0 \u00b1 0 copies / ml ) , decreased inflammatory factors IL-6 , IL-10 , TNF-\u03b1 , and IFN-\u03b3 in the lung , and increased the amount of CD4+ and CD8+ cells in the blood compared to the model group .", "Evidence Elements": {"Participant": [{"term": "HCoV-229E", "negation": "affirmed", "UMLS": {}, "start": 58, "end": 67}], "Intervention": [{"term": "SFJDC", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 5, "has_chemical": [{"text": "shufeng jiedu capsules", "maps_to": "C0006935:capsules", "start": 0, "end": 22, "has_form": ["capsules"]}], "has_relation": "N/A"}], "Outcome": [{"term": "virus load in the lung", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 54}, {"term": "inflammatory factors IL-6", "negation": "affirmed", "UMLS": {}, "start": 132, "end": 157}, {"term": "IL-10", "negation": "affirmed", "UMLS": {}, "start": 160, "end": 165}, {"term": "TNF-\u03b1", "negation": "affirmed", "UMLS": {}, "start": 168, "end": 173}, {"term": "IFN-\u03b3 in the lung", "negation": "affirmed", "UMLS": {}, "start": 180, "end": 197}, {"term": "amount of CD4+ and CD8+ cells in", "negation": "affirmed", "UMLS": {}, "start": 218, "end": 250}], "Observation": [{"term": "significantly reduced", "negation": "affirmed", "UMLS": {}, "start": 6, "end": 27}, {"term": "from 1109.29 \u00b1 696.75 to 0 \u00b1 0", "negation": "affirmed", "UMLS": {}, "start": 75, "end": 105}, {"term": "ml", "negation": "affirmed", "UMLS": {}, "start": 115, "end": 117}, {"term": "decreased", "negation": "affirmed", "UMLS": {}, "start": 122, "end": 131}, {"term": "increased", "negation": "affirmed", "UMLS": {}, "start": 204, "end": 213}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Network analysis revealed that SFJDC reduces the activity of NF\u03baB via several signaling pathways .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "SFJDC", "negation": "affirmed", "UMLS": {}, "start": 31, "end": 36, "has_chemical": [{"text": "shufeng jiedu capsules", "maps_to": "C0006935:capsules", "start": 0, "end": 22, "has_form": ["capsules"]}], "has_relation": "N/A"}], "Outcome": [{"term": "activity of NF\u03baB", "negation": "affirmed", "UMLS": {}, "start": 49, "end": 65}], "Observation": [{"term": "reduces", "negation": "affirmed", "UMLS": {}, "start": 37, "end": 44}], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Quercetin , wogonin , and polydatin bind directly to the main protease ( Mpro ) of SARS-CoV-2 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "Clinical data showed that SFJDC , added to standard antiviral therapy ( AVD ) , significantly reduced the clinical recovery time of COVID-19 and fatigue ( from 3.55 \u00b1 4.09 to 1.19 \u00b1 2.28 days ) as well as cough ( from 5.67 \u00b1 5.64 to 3.47 \u00b1 3.75 ) days compared to AVD alone .", "Evidence Elements": {"Participant": [{"term": "COVID-19", "negation": "affirmed", "UMLS": {}, "start": 132, "end": 140}], "Intervention": [{"term": "SFJDC , added to standard antiviral therapy ( AVD )", "negation": "affirmed", "UMLS": {}, "start": 26, "end": 77, "has_chemical": [{"text": "shufeng jiedu capsules", "maps_to": "C0006935:capsules", "start": 0, "end": 22, "has_form": ["capsules"]}], "has_procedure": [{"text": "standard antiviral therapy", "maps_to": "C0280274:antiviral therapy", "start": 34, "end": 60}], "has_relation": "combined_with (C0006935<->C0280274)"}], "Outcome": [{"term": "clinical recovery time", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 128}, {"term": "fatigue", "negation": "affirmed", "UMLS": {}, "start": 145, "end": 152}, {"term": "cough", "negation": "affirmed", "UMLS": {}, "start": 205, "end": 210}], "Observation": [{"term": "significantly reduced", "negation": "affirmed", "UMLS": {}, "start": 80, "end": 101}, {"term": "from 3.55 \u00b1 4.09 to 1.19 \u00b1 2.28 days", "negation": "affirmed", "UMLS": {}, "start": 155, "end": 191}, {"term": "from 5.67 \u00b1 5.64 to 3.47", "negation": "affirmed", "UMLS": {}, "start": 213, "end": 237}], "Count": []}, "Evidence Propositions": [{"Intervention": {"term": "SFJDC , added to standard antiviral therapy ( AVD )", "has_chemical": [{"text": "shufeng jiedu capsules", "maps_to": "C0006935:capsules", "start": 0, "end": 22, "has_form": ["capsules"]}], "has_procedure": [{"text": "standard antiviral therapy", "maps_to": "C0280274:antiviral therapy", "start": 34, "end": 60}], "has_relation": "combined_with (C0006935<->C0280274)"}, "Observation": "significantly reduced", "Outcome": "clinical recovery time", "Count": ""}, {"Intervention": {"term": "SFJDC , added to standard antiviral therapy ( AVD )", "has_chemical": [{"text": "shufeng jiedu capsules", "maps_to": "C0006935:capsules", "start": 0, "end": 22, "has_form": ["capsules"]}], "has_procedure": [{"text": "standard antiviral therapy", "maps_to": "C0280274:antiviral therapy", "start": 34, "end": 60}], "has_relation": "combined_with (C0006935<->C0280274)"}, "Observation": "significantly reduced", "Outcome": "fatigue", "Count": ""}, {"Intervention": {"term": "SFJDC , added to standard antiviral therapy ( AVD )", "has_chemical": [{"text": "shufeng jiedu capsules", "maps_to": "C0006935:capsules", "start": 0, "end": 22, "has_form": ["capsules"]}], "has_procedure": [{"text": "standard antiviral therapy", "maps_to": "C0280274:antiviral therapy", "start": 34, "end": 60}], "has_relation": "combined_with (C0006935<->C0280274)"}, "Observation": "significantly reduced", "Outcome": "cough", "Count": ""}, {"Intervention": {"term": "SFJDC , added to standard antiviral therapy ( AVD )", "has_chemical": [{"text": "shufeng jiedu capsules", "maps_to": "C0006935:capsules", "start": 0, "end": 22, "has_form": ["capsules"]}], "has_procedure": [{"text": "standard antiviral therapy", "maps_to": "C0280274:antiviral therapy", "start": 34, "end": 60}], "has_relation": "combined_with (C0006935<->C0280274)"}, "Observation": "from 3.55 \u00b1 4.09 to 1.19 \u00b1 2.28 days", "Outcome": "fatigue", "Count": ""}, {"Intervention": {"term": "SFJDC , added to standard antiviral therapy ( AVD )", "has_chemical": [{"text": "shufeng jiedu capsules", "maps_to": "C0006935:capsules", "start": 0, "end": 22, "has_form": ["capsules"]}], "has_procedure": [{"text": "standard antiviral therapy", "maps_to": "C0280274:antiviral therapy", "start": 34, "end": 60}], "has_relation": "combined_with (C0006935<->C0280274)"}, "Observation": "from 5.67 \u00b1 5.64 to 3.47", "Outcome": "cough", "Count": ""}]}, {"Section": "RESULTS", "Text": "SFJDC therapy was significantly more effective when used within the first 8 days after the onset of symptoms .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "SFJDC therapy", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 13, "has_procedure": [{"text": "shufeng jiedu capsules therapy", "maps_to": "C0087111:therapy", "start": 0, "end": 30, "has_form": ["capsules"]}], "has_relation": "N/A"}], "Outcome": [], "Observation": [{"term": "significantly more effective", "negation": "affirmed", "UMLS": {}, "start": 18, "end": 46}], "Count": []}, "Evidence Propositions": [{"Intervention": [{"term": "SFJDC therapy", "has_procedure": [{"text": "shufeng jiedu capsules therapy", "maps_to": "C0087111:therapy", "start": 0, "end": 30, "has_form": ["capsules"]}], "has_relation": "N/A"}], "Observation": "significantly more effective", "Outcome": "", "Count": ""}]}, {"Section": "CONCLUSION", "Text": "SFJDC might be a promising drug for the treatment of COVID-19 , but large-scale randomized , double-blinded , placebo-controlled clinical trials are needed to complement the real-world evidence .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "CONCLUSION", "Text": "It might be beneficial to start SFJDC treatment as early as possible in suspected cases of COVID-19 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Copyright \u00a9 2020 The Author (s ) .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by Elsevier GmbH . . All rights reserved .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}